Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
NCT02530437 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2023-07-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SMO within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-03Results posted on the registry: Sol-Gel Technologies, Ltd., Patidegib Topical Gel, 2% + Patidegib Topical Gel, Vehicle (NCT03703310)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Alectinib + Vismodegib (NCT03498521)
- 2024-04-25Results posted on the registry: Pfizer, PF-04449913 (NCT00953758)
- 2024-03-06Results posted on the registry: Pfizer, PF-04449913 (NCT01286467)
- 2024-03-04Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Abiraterone (NCT03878524)
- 2024-01-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Alectinib + Alpelisib (NCT05238831)
- 2023-12-18Results posted on the registry: Pfizer, Glasdegib + Azacitidine (NCT04842604)
- 2023-09-22Phase 3 first posted: Sol-Gel Technologies, Ltd., Patidegib Topical Gel + Patidegib Topical Gel with no active patidegib (NCT06050122)
- 2023-05-24Results posted on the registry: M.D. Anderson Cancer Center, Anti-OX40 Agonist Monoclonal Antibody PF-04518600 + Avelumab (NCT03390296)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision